1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
MabCure Inc.

MabCure Inc.

MBCI
MabCure Inc.US flagOther OTC
0.00
USD
- -
- -
21,965.00Market Cap
MabCure Inc.
MBCI
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2006
2007
2008
2009
2010
2011
TTM
FRC
- -
- -
- -
- -
- -
- -
0.01
Revenue per Share
- -
- -
-0.01
-0.02
-0.02
- -
-0.19
Basic EPS, GAAP
- -
- -
-0.01
-0.02
-0.01
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-0.01
-0.03
-0.05
- -
-0.24
Book Value per Share
0.01
- -
0.02
-0.01
- -
- -
-0.01
Tangible Book Value per Share
8
50
43
60
62
- -
63
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-141.95
-141.78
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
-1
-1
-1
-12
-12
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-2,452.97
-2,452.8
Profit Margin (%)
- -
- -
1
- -
- -
-1
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
19
16
16
4
4
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'11
Sep'11
Dec'11
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
64
64
62
Market Capitalization
14
9
4

Working Capital

FRC

•

in mil. unless spec.
Jun'11
Sep'11
Dec'11
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-7,875.6%
-75.35%
Free Cash Flow
- -
387.73%
-91.19%
Net Income, GAAP
- -
801.15%
900.56%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
-0.01
- -
-0.02
2010
- -
- -
-0.01
- -
-0.02
2011
-0.01
-0.01
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -
Similar Companies
Emmessar Biotech & Nutrition Limited (EMMESSA.BO)
Alternative Energy Partners, Inc. (AEGY)
Boryung Corporation (003850.KS)
Pharmaron Beijing Co., Ltd. (300759.SZ)
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (603811.SS)
JW Lifescience Corporation (234080.KS)
Business
MabCure, Inc. (MBCI) is a development-stage biotechnology company that develops and commercializes proprietary antibody technology for the early detection of cancer and the creation of specific therapeutics against cancer; it owns technology for generating monoclonal antibodies targeting cancer markers such as those for ovarian and prostate cancers. The company offers diagnostic tools, imaging agents, and potential therapeutic drugs derived from these highly specific monoclonal antibodies. Founded in 2006 and headquartered in White Plains, New York, with a historical wholly-owned subsidiary MabCure N.V. in Belgium, MabCure previously known as Smartec Holdings, Inc., changed its name in January 2008 to align with its biotechnology focus following the acquisition of monoclonal antibody generation technology; it established the Belgian subsidiary in 2008 to accelerate research and commercialization efforts, including collaborations with European medical centers for clinical trials on ovarian cancer diagnostics.